The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels

Pineal Gland and Tumor Cell Kinetics: Serum Levels of Melatonin in Relation to Ki-67 Labeling Rate in Breast Cancer

“…In agreement with the results previously reported by other authors [14] and by ourselves [9], high blood levels of melatonin can often be observed in breast cancer women. Moreover, this study shows that breast cancer patients with positive ki-67 labeling rate tend to present lower blood levels of the pineal hormone, melatonin, in respect to the negative ones.…”

Pineal Gland and Tumor Cell Kinetics: Serum Levels of Melatonin in Relation to Ki-67 Labeling Rate in Breast Cancer

“…In agreement with the results previously reported by other authors [14] and by ourselves [9], high blood levels of melatonin can often be observed in breast cancer women. Moreover, this study shows that breast cancer patients with positive ki-67 labeling rate tend to present lower blood levels of the pineal hormone, melatonin, in respect to the negative ones.…”

Plasma Melatonin in Patients with Breast Cancer

“…The mean values documented in our study are also higher than our laboratory mean for normal individuals which is 18.4 ± 1.56 pg/ml. However, our results did not concur with the observation of Lissoni et al [19] that patients with solid tumors without métastasés showed higher mean melatonin serum levels than those observed in patients with métastasés and that melatonin secretion decreases progressively with tumor development. Data from our study showed statistically significantly lower mela tonin levels in the patient in the adjuvant group when compared to those in the metastatic disease group, regardless of w hether the metastatic group's patients were in remission or not.…”

“…than in those whose disease is controlled or stable. It is known that melatonin blood levels are altered in oncological patients and that they change in relation to tumor growth [19]. The data of Raikhlin et al [16] and Lissoni et al [17.…”

Seasonal changes in serum melatonin in women with previous breast cancer

“…Other researchers have noted differences in total melatonin secretion between women with breast cancer and controls (Bartsch et al, 1981(Bartsch et al, , 1989 (Lissoni et al, 1987). In the present study it is uncertain how many women may have had early metastatic disease at the time of study (30% had been node positive at initial surgery), but all were free of clinically apparent breast cancer.…”

Pineal Gland and Tumor Cell Kinetics: Serum Levels of Melatonin in Relation to Ki-67 Labeling Rate in Breast Cancer

“…In agreement with the results previously reported by other authors [14] and by ourselves [9], high blood levels of melatonin can often be observed in breast cancer women. Moreover, this study shows that breast cancer patients with positive ki-67 labeling rate tend to present lower blood levels of the pineal hormone, melatonin, in respect to the negative ones.…”

Plasma Melatonin in Patients with Breast Cancer

“…The mean values documented in our study are also higher than our laboratory mean for normal individuals which is 18.4 ± 1.56 pg/ml. However, our results did not concur with the observation of Lissoni et al [19] that patients with solid tumors without métastasés showed higher mean melatonin serum levels than those observed in patients with métastasés and that melatonin secretion decreases progressively with tumor development. Data from our study showed statistically significantly lower mela tonin levels in the patient in the adjuvant group when compared to those in the metastatic disease group, regardless of w hether the metastatic group's patients were in remission or not.…”

“…than in those whose disease is controlled or stable. It is known that melatonin blood levels are altered in oncological patients and that they change in relation to tumor growth [19]. The data of Raikhlin et al [16] and Lissoni et al [17.…”

Seasonal changes in serum melatonin in women with previous breast cancer

“…Other researchers have noted differences in total melatonin secretion between women with breast cancer and controls (Bartsch et al, 1981(Bartsch et al, , 1989 (Lissoni et al, 1987). In the present study it is uncertain how many women may have had early metastatic disease at the time of study (30% had been node positive at initial surgery), but all were free of clinically apparent breast cancer.…”

Pineal Gland and Tumor Cell Kinetics: Serum Levels of Melatonin in Relation to Ki-67 Labeling Rate in Breast Cancer

“…In agreement with the results previously reported by other authors [14] and by ourselves [9], high blood levels of melatonin can often be observed in breast cancer women. Moreover, this study shows that breast cancer patients with positive ki-67 labeling rate tend to present lower blood levels of the pineal hormone, melatonin, in respect to the negative ones.…”

Plasma Melatonin in Patients with Breast Cancer

“…The mean values documented in our study are also higher than our laboratory mean for normal individuals which is 18.4 ± 1.56 pg/ml. However, our results did not concur with the observation of Lissoni et al [19] that patients with solid tumors without métastasés showed higher mean melatonin serum levels than those observed in patients with métastasés and that melatonin secretion decreases progressively with tumor development. Data from our study showed statistically significantly lower mela tonin levels in the patient in the adjuvant group when compared to those in the metastatic disease group, regardless of w hether the metastatic group's patients were in remission or not.…”

“…than in those whose disease is controlled or stable. It is known that melatonin blood levels are altered in oncological patients and that they change in relation to tumor growth [19]. The data of Raikhlin et al [16] and Lissoni et al [17.…”

Seasonal changes in serum melatonin in women with previous breast cancer

“…Other researchers have noted differences in total melatonin secretion between women with breast cancer and controls (Bartsch et al, 1981(Bartsch et al, , 1989 (Lissoni et al, 1987). In the present study it is uncertain how many women may have had early metastatic disease at the time of study (30% had been node positive at initial surgery), but all were free of clinically apparent breast cancer.…”